INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2008

Oral curcumin was well tolerated and showed biological activity in advanced pancreatic cancer

Twenty-five patients with advanced pancreatic cancer received 8 g of oral curcumin daily until progression. Circulating conjugates peaked at 22 to 41 ng/mL, reflecting poor bioavailability. Two of 21 evaluable participants showed biological activity, including one individual with stable disease exceeding 18 months and another with a temporary 73% tumor reduction. Curcumin down-regulated peripheral mononuclear cell expression of NF-kappaB, COX-2, and pSTAT3 without causing toxicities.

Study type
Phase II trial
Who was studied
25 patients with advanced pancreatic cancer
What was measured
Clinical biological activity and tumor response

THE PAPER

Phase II trial of curcumin in patients with advanced pancreatic cancer.

Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Clin Cancer Res, 2008.

PubMed 18628464 ↗DOI 10.1158/1078-0432.CCR-08-0024 ↗

Cancer

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.